Ameresco Generates over $70 Million in Cash Proceeds from Sale of RNG-Related Investment Tax Credits
FRAMINGHAM, Mass.--(BUSINESS WIRE)-- Ameresco, Inc., (NYSE: AMRC), a leading energy solutions provider dedicated to helping customers navigate the energy transition today announced the successful sale of approximately $71 million in Investment Tax Credits (ITCs) generated from three of its landfill-gas-to-renewable natural gas (RNG) projects. These projects, which Ameresco developed, constructed, financed, and currently operates, were placed in service in 2024.
This transaction marks Ameresco's third ITC sale to a corporate buyer and its first sale of RNG tax credits under the transferability rules, demonstrating the company's ability to capitalize on clean energy incentives and project financing through multiple means and a diversified pool of lenders and investors.
'We are excited to complete our first RNG tax credit sale, which reflects the growing value and market confidence in renewable natural gas as a critical component of the clean energy transition,' said Mike Bakas, President of Renewable Fuels at Ameresco. 'This milestone builds on our recent success monetizing solar and battery storage tax credits, including our landmark transaction with MassMutual, and demonstrates our ability to leverage a variety of financial structures to unlock value from our energy assets.'
STX Group served as the exclusive facilitator for Ameresco in this transaction.
Ameresco remains committed to advancing sustainable energy solutions and will continue to explore opportunities to monetize its diverse portfolio of energy assets.
For more information about Ameresco and its firm, renewable fuel solutions, visit www.ameresco.com/renewable-natural-gas.
About Ameresco, Inc.
Founded in 2000, Ameresco, Inc. (NYSE: AMRC) is a leading energy solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the global energy transition. Our comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. As a trusted full-service partner, Ameresco shows the way by reducing energy use and delivering diversified generation solutions to Federal, state and local governments, utilities, educational and healthcare institutions, housing authorities, and commercial and industrial customers. Headquartered in Framingham, MA, Ameresco has more than 1,500 employees providing local expertise in North America and Europe. For more information, visit www.ameresco.com.
About STX Group
STX Group is a leading global environmental commodity trader and climate solutions provider. For over 25 years, STX has been at the forefront of the global transition toward a low-carbon economy. By leveraging deep expertise in pricing pollution and emissions, STX helps cultivate trust in market-based solutions and accelerates capital flows into projects that make the world a greener place. Its trading and corporate climate solutions empower organizations to meet environmental goals with certified proof points and measurable impact. With a strong presence in the U.S.—including offices in New York and Houston—STX combines global reach with local expertise to connect participants across the full environmental commodity value chain.
For more information, please visit stxgroup.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Better Cybersecurity Stock: CrowdStrike or SentinelOne?
CrowdStrike and SentinelOne have similar business models and offerings. CrowdStrike is much larger. SentinelOne trades at a steep discount to CrowdStrike. 10 stocks we like better than CrowdStrike › Artificial intelligence (AI) may have many benefits, but it's also making it easier for hackers, online criminals, and other digital malefactors to threaten businesses, and those threats are getting more potent. Keeping them at bay requires a lot of funds to be devoted to cybersecurity, making companies like CrowdStrike (NASDAQ: CRWD) and SentinelOne (NYSE: S) excellent investment opportunities. But is there an advantage to buying one over the other now? Both companies' base products are AI-powered protection platforms that analyze digital activity and learn to spot the threats among the normal activity. They deploy their software to network endpoints -- in other words, laptops, smartphones, and other devices that can access a client's internal network. By protecting these devices, companies make it harder for cyberattackers to gain access to their internal networks, where they might steal sensitive information, delete files, interfere with systems, or even lock them down with ransomware to extort payments from their victims. While endpoint protection is how both companies land clients, each bolsters its offerings with an array of other cybersecurity products that clients can use to create a protection suite tailored to their unique situations. Since these two direct competitors offer highly similar product types, it's hard to declare either a winner on this front from an investor perspective. Winner: Tie. From a sheer size perspective, CrowdStrike is the clear winner. During its fiscal 2026 first quarter, which ended April 30, CrowdStrike's annual recurring revenue (ARR) rose to $4.4 billion. SentinelOne's ARR of $948 million in its fiscal Q1 was less than a quarter of that. While size doesn't always matter, in this case, it does. Because so many more companies use CrowdStrike's platform, it's more likely that any given IT professional will have at least one contact already on its client list. If CrowdStrike is doing a great job with those clients, word will spread, and it will likely receive more serious consideration in future cybersecurity bidding processes. This advantage cannot be understated. Indeed, it's one of the reasons why CrowdStrike's growth has remained strong despite its size. Winner: CrowdStrike In terms of growth rates, SentinelOne is slightly outperforming CrowdStrike in this category. However, this should be no surprise because SentinelOne is a much smaller company. In fiscal Q1, SentinelOne's ARR rose 24% year over year, while CrowdStrike's increased 22% year over year. While I will give the point to SentinelOne, it's important to understand that CrowdStrike is growing from a much larger base than SentinelOne, making this close call all the more impressive for CrowdStrike. Winner: SentinelOne Due to its smaller size and focus on top-line growth, SentinelOne is far from profitable, while CrowdStrike has achieved intermittent profitability (although it reverted to a negative operating margin and a loss in its most recent quarter). SentinelOne is far from breaking even, but CrowdStrike was in this same position about five years ago. There's no reason not to expect SentinelOne to follow a similar path to profitability, but it will take some time. Meanwhile, CrowdStrike should eventually turn a profit again, as it has proven that it can do that. Winner: CrowdStrike CrowdStrike is leading this battle of the stocks so far, but SentinelOne is about to change the narrative with one jaw-dropping metric. CrowdStrike is the most popular cybersecurity stock in the market, and as a result, it has been bid up to expensive levels. From a price-to-sales (P/S) standpoint (the best metric to use to compare these companies since CrowdStrike flips between profitable and unprofitable, while SentinelOne is years away from profits), CrowdStrike has gotten far more expensive than SentinelOne over the past few years. CrowdStrike stock is now five times more expensive than SentinelOne, which is hard to believe, considering they compete in the same industry and are growing at nearly identical rates. This leads me to believe that CrowdStrike's stock has been overly hyped up while SentinelOne has been forgotten. While I'm OK with valuing CrowdStrike at a premium due to its market leadership position, this is far too great a premium to pay. SentinelOne is a dirt-cheap stock, and CrowdStrike is almost too expensive to consider. While I have been a long-term CrowdStrike bull, I'd be a bit cautious about buying the stock at its current lofty valuation. As a result, I think SentinelOne is the better cybersecurity investment right now. Before you buy stock in CrowdStrike, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CrowdStrike wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Keithen Drury has positions in CrowdStrike. The Motley Fool has positions in and recommends CrowdStrike. The Motley Fool has a disclosure policy. Better Cybersecurity Stock: CrowdStrike or SentinelOne? was originally published by The Motley Fool Sign in to access your portfolio
Business Upturn
3 hours ago
- Business Upturn
OGN FRAUD ALERT: Organon & Co. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 22 Legal Deadline (NYSE:OGN)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting Investors have until July 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities. The case is pending in the U.S. District Court for the District of New Jersey and is captioned: Hauser v. Organon & Co., et al. , No. 25-cv-05322. Why was Organon Sued for Securities Fraud? Organon is a global healthcare company focused on women's health that has historically rewarded its shareholders with a healthy dividend. In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company focused on dermatological conditions. As alleged, while the acquisition increased Organon's debt, the Company assured investors it would maintain its dividend, which Organon asserted was its '#1 capital allocation priority.' In truth, Organon had shifted its capital allocation priority after the Dermavant acquisition to focus on reducing its debt, ultimately leading the Company to severely cut its dividend. The Stock Declines as the Truth is Revealed On May 1, 2025, Organon announced that management reset the Company's dividend payout from $0.28 per share to $0.02 per share. Organon's CEO explained that the Company 'reset our capital allocation priorities to accelerate progress towards deleveraging' and that '[b]y deleveraging more rapidly, we will continue to strengthen the future prospects of the company.' Organon's CFO added, '[t]he biggest issues we face . . . relate to managing our leverage and relate to growth. And we need capital to solve both of those issues, and so returning capital to shareholders is right now, less of a priority.' On this news, the price of Organon stock declined roughly 27%, from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025. Click here if you suffered losses: What Can You Do? If you invested in Organon you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Business Upturn
3 hours ago
- Business Upturn
IOVA FRAUD ALERT: Iovance Biotherapeutics Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 14 Legal Deadline (NASDAQ:IOVA)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting Investors have until July 14, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Iovance securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sundaram v. Iovance Biotherapeutics, Inc., et al. , No. 25-cv-04177. Why was Iovance Sued for Securities Fraud? Iovance is a commercial-stage biopharmaceutical company focused on the development of treatments for melanoma and other solid tumor cancers. The Company commercially launched its key melanoma treatment Amtagvi in February 2024. Iovance administers Amtagvi at the Company's authorized treatment centers ('ATCs'). As alleged, Iovance repeatedly touted its ATCs as a driver of demand for Amtagvi. In truth, Iovance's ATCs were experiencing long timelines to begin treating patients with Amtagvi, and ineffective patient identification and patient selection for treatment was causing high patient drop-offs at the ATCs. The Stock Declines as the Truth is Revealed On May 8, 2025, Iovance reported disappointing financial results for 1Q25 and announced it was 'revising full-year 2025 revenue guidance.' The Company blamed 'recent launch dynamics,' including slow 'treatment timelines for new ATCs' and 'the variable pace at which ATCs began treating patients,' which 'differs from center to center.' Iovance also blamed the poor results on high 'patient drop-off' due to inadequate 'patient selection' for treatment. On this news, the price of Iovance stock declined more than 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025. Click here if you suffered losses: What Can You Do? If you invested in Iovance you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
